Replies to post #215345 on Biotech Values

[Bickema]

ENTA is looking at roughly 35 mil cash burn per quarter for fiscal year 2018. High end of guidance. Maybe wait on a dividend until Mavyret drives strong revenues and EDP-305 gets a partner.

It looked like the market liked the strong jump in script numbers, nice to see

Research and development expense between $90 million and $110 million
General and administration expense between $22 million and $28 million